Avian Metapneumovirus

Avian metapneumovirus (AMPV) is a highly contagious upper respiratory disease affecting global poultry, known variably as avian rhinotracheitis, turkey rhinotracheitis, or swollen head syndrome based on subtype and host species. AMPV first surfaced in South African turkeys in the late 1970s as subtype A and has since expanded to include subtypes A, B, C, and D (MacLachlan, James, and Dubovi, 2017). Subtype C initially appeared in US turkeys in the late 1990s, with subsequent decreased outbreaks post-2007 due to improved biosecurity and vaccination measures (Yu, 2012).

The US is currently facing a new AMPV outbreak involving subtypes A and B, affecting commercial farms in 9 states: North Carolina, South Carolina, Virginia, West Virginia, Pennsylvania, Michigan, Georgia, California, and Texas, impacting turkeys, broilers, broiler breeders, and table egg layers.

AMPV primarily targets the upper respiratory tract, exhibiting clinical signs like conjunctivitis, nasal exudate, and periorbital swelling (Amine et al., 2023). Secondary infections, such as E. coli, may arise due to immunosuppression and respiratory system damage. Chickens typically display initial signs of sneezing, rales, and excessive tear production, while turkeys often exhibit edema around the eyes and nasal discharge. Reduced egg production, poor eggshell quality, and egg yolk peritonitis are also observed in turkey hens and broiler breeders. Morbidity can reach 100%, with mortality varying from 0.4% to 50% depending on co-infections (Rautenschlein, 2020).

Distinguishing AMPV from other respiratory diseases like Avian Influenza, Infectious Coryza, or M. gallisepticum based solely on clinical signs is challenging, so diagnostic testing is crucial in proper identification. Serologic and antigen tests are available across US labs, with sample collection recommended three to five days post-infection to enhance virus detection and isolation (Amine et al., 2023).

While no specific treatment exists for AMPV, managing secondary infections can be beneficial. Currently, no commercial AMPV vaccines are licensed in the US. Implementing robust biosecurity measures, effective management practices, and regular testing protocols are pivotal in curbing virus spread.

Citations

  • Amine Mernizi, Hicham Fathi, Juan Luis Criado, Mohammed Bouslikhane, Abdeljelil Ghram, Mohammed Mouahid & Saadia Nassik. 2023. Avian Metapneumovirus Review: A Focus on Broilers. Poult. Sci. J. 11(1): 1-17. 
  • Yu, Q. 2012. Avian metapneumovirus in the USA. Review Article. 2012 CDROM.
  • MacLachlan, N. James, and Edward J. Dubovi (Editors). "Chapter 17 - Paramyxoviridae and Pneumoviridae." Fenner's Veterinary Virology, 5th edition, Academic Press, 2017, pp. 327-356. ISBN 9780128009468.
  • Rautenschlein S. Avian metapneumovirus. In: Swayne D.E., editor. Diseases of Poultry, 14th ed. Wiley Blackwell; Hoboken, NJ, USA: 2020. pp. 135–143.

Published on

15 April 2024

Tags

  • Poultry

Related Articles

  • Highly Pathogenic Avian Influenza

    Highly Pathogenic Avian Influenza

    19 Feb 2024

    Highly Pathogenic Avian Influenza (HPAI) presents a worldwide challenge to the poultry industry due to its extensive spread and high death rates. The transformation of low-pathogenic avian influenza (LPAI) viruses into HPAI forms has been an important aspect of their evolutionary history, greatly impacting avian populations worldwide (Lee, Criado, & Swayne, 2020). Particularly virulent strains of avian flu, such as H5N1, have been responsible for major bird epidemics (Charostad, 2023). The article discusses HPAI epidemiological status and evidence-based strategies for its prevention and control.

  • Mycotoxins as Predisposing Factors to Health Challenges

    Mycotoxins as Predisposing Factors to Health Challenges

    22 Jan 2024

    The negative impacts of mycotoxins in poultry can be far-reaching, decreasing gastrointestinal integrity, immunity and performance in broilers, thus resulting in economic losses. Given the high prevalence rates of contamination in poultry feed, a mycotoxin risk management strategy is needed to reduce the challenges in poultry production and ensure profitability. Poultry producers frequently ask: What is the real impact of mycotoxins on the bird’s productivity? What sounds like an easy question is, in the case of mycotoxins, unfortunately not so easy to answer. A key consideration to evaluate the impact of mycotoxins includes mycotoxins as potential predisposing factors to health challenges.

  •  Optimizing Strategies to Manage Coccidiosis in Poultry: Why and How Your Control Program Needs to Adapt

    Optimizing Strategies to Manage Coccidiosis in Poultry: Why and How Your Control Program Needs to Adapt

    20 Nov 2023

    The estimated cost of coccidiosis globally is between USD 9.2 and 15.6 billion, or approximately USD 0.2 per chicken (Blake et al., 2020). This estimate is derived not only from the cost of prophylactics and therapeutics, but also the associated performance and mortality loss. Additional losses due to secondary challenges associated with coccidiosis may also increase the overall economic impact. Many protozoa plague the livestock industry but, in poultry, there are seven Eimeria species of the protozoal parasite coccidia that infect different regions in the intestinal tract (Shirley et al., 1986). Regardless of the site of infection, Eimeria have a complex life cycle that includes stages within the bird and environment. Depending on the Eimeria species, site of infection and life cycle stage, certain prevention strategies may be more effective than others (Chapman and Rathinam, 2022).

Share

You are being redirected.

We detected that you are visitng this page from United States. Therefore we are redirecting you to the localized version.